SG11201903100TA - Method of preparing peptides comprising a lipophilically modified lysine side chain - Google Patents

Method of preparing peptides comprising a lipophilically modified lysine side chain

Info

Publication number
SG11201903100TA
SG11201903100TA SG11201903100TA SG11201903100TA SG11201903100TA SG 11201903100T A SG11201903100T A SG 11201903100TA SG 11201903100T A SG11201903100T A SG 11201903100TA SG 11201903100T A SG11201903100T A SG 11201903100TA SG 11201903100T A SG11201903100T A SG 11201903100TA
Authority
SG
Singapore
Prior art keywords
co7k
international
sanofi
frankfurt
pct
Prior art date
Application number
SG11201903100TA
Other languages
English (en)
Inventor
Bernd Henkel
Norbert Pleuss
Rolf-Ludwig Hoerlein
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201903100TA publication Critical patent/SG11201903100TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
SG11201903100TA 2016-10-10 2017-10-10 Method of preparing peptides comprising a lipophilically modified lysine side chain SG11201903100TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306332 2016-10-10
PCT/EP2017/075773 WO2018069295A1 (en) 2016-10-10 2017-10-10 Method of preparing peptides comprising a lipophilically modified lysine side chain

Publications (1)

Publication Number Publication Date
SG11201903100TA true SG11201903100TA (en) 2019-05-30

Family

ID=57153433

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903100TA SG11201903100TA (en) 2016-10-10 2017-10-10 Method of preparing peptides comprising a lipophilically modified lysine side chain

Country Status (15)

Country Link
US (1) US11021512B2 (zh)
EP (1) EP3523324B1 (zh)
JP (1) JP2019533666A (zh)
KR (1) KR20190059321A (zh)
CN (1) CN109790208A (zh)
AR (1) AR109914A1 (zh)
AU (1) AU2017341951B2 (zh)
BR (1) BR112019007063A2 (zh)
CA (1) CA3039752A1 (zh)
IL (1) IL265888A (zh)
MX (1) MX2019004116A (zh)
RU (1) RU2755543C2 (zh)
SG (1) SG11201903100TA (zh)
TW (1) TW201821434A (zh)
WO (1) WO2018069295A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010715A (es) 2018-04-10 2021-01-08 Sanofi Aventis Deutschland Sintesis de lixisenatida con taponamiento.
WO2019197466A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
CN110183531A (zh) * 2019-05-17 2019-08-30 河北常山生化药业股份有限公司 一种艾本那肽前体的制备方法
CN111704654B (zh) * 2020-06-18 2021-12-03 上海交通大学医学院附属仁济医院 肽类化合物及其制备方法与应用
WO2024156694A1 (en) 2023-01-24 2024-08-02 Boehringer Ingelheim International Gmbh Method for synthesizing polypeptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US8614182B2 (en) * 2009-07-30 2013-12-24 Jiangsu Hansoh Pharmaceuticals Co., Ltd. GLP-1 analogues and their pharmaceutical salts and uses
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
FR2952695B1 (fr) 2009-11-13 2012-03-30 Commissariat Energie Atomique Reservoir de stockage d'hydrogene a hydrures metalliques
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
EP2539364A1 (en) * 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
EA201590011A1 (ru) 2012-06-14 2015-05-29 Санофи Пептидные аналоги эксендина-4
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑

Also Published As

Publication number Publication date
AR109914A1 (es) 2019-02-06
RU2019113729A3 (zh) 2021-02-20
TW201821434A (zh) 2018-06-16
RU2755543C2 (ru) 2021-09-17
AU2017341951A1 (en) 2019-05-30
CA3039752A1 (en) 2018-04-19
US11021512B2 (en) 2021-06-01
KR20190059321A (ko) 2019-05-30
EP3523324A1 (en) 2019-08-14
RU2019113729A (ru) 2020-11-13
WO2018069295A1 (en) 2018-04-19
EP3523324B1 (en) 2021-09-22
MX2019004116A (es) 2019-08-12
CN109790208A (zh) 2019-05-21
JP2019533666A (ja) 2019-11-21
BR112019007063A2 (pt) 2019-11-26
US20200024304A1 (en) 2020-01-23
IL265888A (en) 2019-06-30
AU2017341951B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
SG11201903100TA (en) Method of preparing peptides comprising a lipophilically modified lysine side chain
SG11201807912SA (en) Vaccine against rsv
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201408746XA (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808108XA (en) Synthesis of indazoles
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201805001UA (en) Method of treating influenza a
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201805191SA (en) Yeast cell
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201809630RA (en) Nicotine particles
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation